With the rapid development of pharmaceutical preparation industry, pharmaceutical product manufacturing enterprises have obviously been increasing demands for new pharmaceutical excipients with high safety, effectiveness, quality controllability and drug use compliance due to considerations such as preparation innovation, shortening of production time and process route and reducing of manufacturing cost. The traditional pharmaceutical excipients represented by the old three "starch, dextrin and sucrose" still occupy a relatively large sales volume, but the growth speed is obviously lower than that of new pharmaceutical excipients. According to statistics of China Pharmaceutical Excipients Committee, the average growth of medicinal starch, dextrin and sucrose in recent three years (2010-2012) was 7%, which was about 1/3 of the concurrent average growth of Chinese pharmaceutical preparation industry; while the annual sales growth of the new common pharmaceutical excipients was over 20%~30%, represented by microcrystalline cellulose, hyprolose, carboxymethyl starch sodium, hydroxypropyl methylcellulose and polyvinylpolypyrrolidone, etc. It is an obvious trend that new pharmaceutical excipients are substituting traditional pharmaceutical excipients.
The international excipients giants have coveted the huge development space of Chinese pharmaceutical excipients market and competed to grab this "big cake", which is sufficient to prove that Chinese pharmaceutical excipients industry is never a dispensable pharmaceutical "supporting role". The traditional pharmaceutical excipients constitute a market; however, the new pharmaceutical excipients start to occupy the market, as we can learn from the above.
